This renewal is a standard part of the ACMPR process, and was granted after Health Canada’s recent inspection of Organigram’s facilities and cultivation methodologies. “We approached this latest inspection with more confidence than we have ever had in the past” stated Organigram CEO Greg Engel. “Considering the process improvements made by the team with the ongoing support and assistance of Health Canada, the level of comfort Canadian medical marijuana patients should have in Organigram is as high as any licensed producer in the Country.” Engel concluded “the Organigram team allowed no margin of error in this latest inspection.” 

The company has taken the concept of “Canada’s Safest Cannabis” as an internal mantra, rolling out several multi-departmental initiatives as a strategy to commit to full transparency and quality control. The first initiative is slotted to begin in the coming weeks, with full Certification of Analysis being posted for clients’ review through Organigram’s client portal. “Client confidence and comfort are our only metrics for these initiatives” noted Engel. “We’ll continue to challenge ourselves to find new and creative ways to assure Canadians that Organigram produces the highest quality, most consistent and safest products available.” 

The Company is also pleased to announce that Organigram’s expansion project remains on target for completion in calendar Q4 2017. The project will add 110,000 square feet to its state-of-the-art production facility in Moncton, New Brunswick. Upon completion of this phase, the Company will have capacity to produce up to 16,000 kgs of cannabis. 

For more information visit www.organigram.ca.